Imbria Pharmaceuticals Appoints John Young to Its Board of Directors

BOSTON--(BUSINESS WIRE)-- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced the appointment of biopharmaceutical industry veteran John Young to its board of directors.

“We are extremely pleased to welcome John to our board of directors,” said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals. “John brings over three decades of experience from his extensive and multifaceted career of proven leadership, strategic acumen, business development and expertise in the clinical advancement and worldwide market potential of innovative medicines across various therapeutic areas. We believe his insights and experience will be invaluable as we continue to execute on our mission to bring new therapeutic options to patients with serious cardio-metabolic diseases.”

“I am honored to join the Imbria board of directors and to work alongside a team that has such deep expertise in both rare and common cardiac diseases. I am very excited about Imbria’s approach with its lead asset, ninerafaxstat, which is differentiated and uniquely positioned to bring value to patients and providers who are looking for new treatment options to improve cardiac energetics and function,” said Mr. Young. “I look forward to partnering with the board and leadership team during this pivotal time and helping to guide them through the next phase of the company’s development.”

John Young currently serves as group president and senior advisor to the Pfizer chief executive officer prior to his retirement from Pfizer in mid-2022. A scientist by training, John has almost 35 years of experience with Pfizer and has held several senior positions across the organization. Most recently, John was group president, chief business officer at Pfizer. He also played an integral role in the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine. Prior to this role, John was the group president of Pfizer Innovative Health, which included six business units focused on developing innovative medicines or vaccines, and on increasing access for patients impacted by diseases with significant unmet need. John will serve as a member of the board of directors of Haleon, the Consumer Healthcare Joint Venture between GlaxoSmithKline and Pfizer when it is separated later this year. He also serves on the board of Johnson Controls International (JCI). John holds a BSc in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.

About Imbria Pharmaceuticals

Imbria is a privately held, clinical stage, cardio-metabolic company focused on improving energy production in the mitochondria and balancing the energy supply and demand of the heart through the development of novel therapies designed to substantially improve the lives of patients with life-altering diseases. Our lead product, ninerafaxstat (formerly IMB-101), is a novel partial fatty acid oxidation inhibitor (pFOXi) in development for a range of cardiac diseases characterized by a mismatch between energy supply and demand. Imbria is currently investigating ninerafaxstat in three Phase 2 proof of concept, indication enabling trials. IMPROVE-DiCE is a target engagement Phase 2 study in patients with diabetes at high risk of heart failure and patients with heart failure with preserved ejection fraction. Imbria also has two randomized, controlled Phase 2 clinical trials currently enrolling patients. IMPROVE-HCM in the orphan indication, non-obstructive hypertrophic cardiomyopathy and IMPROVE-ISCHEMIA in stable angina. The pipeline also includes IMB-203, designed to address energy deficiency in patients with rare inborn errors of mitochondrial metabolism. For additional information, please visit www.imbria.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005189/en/